Spectrum Pharma (SPPI) Reports In-Line Q2 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. LITE
4. AAPL
5. ABBV
6. MRVL
7. CL
8. LYB
9. TFII
10. SPY

Go back to Spectrum Pharma (SPPI) Reports In-Line Q2 EPS

Spectrum Pharmaceuticals Reports Second Quarter 2018 Financial Results and Pipeline Update

August 9, 2018 4:00 PM EDT

An oral presentation of updated Phase 2 poziotinib data including EGFR and HER2 patients with exon 20 mutations will occur on September 24 at the World Conference on Lung Cancer in Toronto Spectrums current poziotinib Phase 2 study is viewed as the pivotal registrational trial following recent conversations with the FDA Both Phase 3 ROLONTIS® (eflapegrastim) studies, RECOVER and ADVANCE, have met the primary efficacy endpoint; Spectrum is preparing for a pre-BLA meeting with the FDA in the third quarter Q2 revenues were $24.2 million, including $23.8 million in product sales... More